Sanofi: accelerated review of two combination vaccine candidates
(CercleFinance.com) - Sanofi reports that the US FDA has granted accelerated review to two combination vaccine candidates, the first non-mRNAs combining two licensed vaccines for the prevention of influenza and Covid-19 infections, in adults aged 50 and over.
The first combines Fluzone High-Dose trivalent protein-based influenza vaccine with Novavax, a recombinant adjuvanted Covid-19 vaccine, and the second, Flublok trivalent recombinant protein-based vaccine with Novavax Covid-19 vaccine.
Sanofi has initiated two separate Phase I/II, parallel, randomized, double-blind, modified, multiple-arm studies to evaluate the safety of the two combined vaccine candidates, as well as the immune response they induce.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The first combines Fluzone High-Dose trivalent protein-based influenza vaccine with Novavax, a recombinant adjuvanted Covid-19 vaccine, and the second, Flublok trivalent recombinant protein-based vaccine with Novavax Covid-19 vaccine.
Sanofi has initiated two separate Phase I/II, parallel, randomized, double-blind, modified, multiple-arm studies to evaluate the safety of the two combined vaccine candidates, as well as the immune response they induce.
Copyright (c) 2024 CercleFinance.com. All rights reserved.